Data from the PARTNER 3 trial continues to prove the Edwards SAPIEN 3 platform is the choice for lifetime management – from the index procedure and beyond.
*For patients assessed at high-risk for surgical replacement.
Your strategy for lifetime management starts with the Edwards SAPIEN 3 platform. When the first valve choice matters, the SAPIEN 3 platform is designed to deliver a reliable TAVI experience so patients can live their best lives.1,2,3
Explore Edwards SAPIEN 3 platform for lifetime management
Industry experts share the latest interventional techniques and provide their advice on how best to adopt them within clinical practice.
About our programsEdwards Benchmark Program
Our program may support your heart centre in optimising its transcatheter aortic valve implantation (TAVI) care pathway for better patient outcomes.
Learn moreTips and Techniques
Explore case recordings, expert-delivered educational videos on procedural challenges, tips and techniques, peer interviews and more.
View videosLearning Portal
Edwards Learning Network, an educational portal for healthcare professionals providing continuous learning and development in structural heart intervention.
Find out more
The latest transcathether heart valve in the
The first TAVI valve to receive a CE mark for severe aortic stenosis (sAS) patients at low surgical risk.
Edwards valve proving non-inferior to surgery on mortality and stroke in the PARTNER IIA Trial.4
Introduced as a lifesaving treatment option for inoperable and high surgical risk patients.5,6
Overview of studies conducted with balloon expandable TAVI valves by Edwards Lifesciences.
Read PARTNER dataLearn how the Edwards clinical trial programme has shaped the aortic stenosis treatment landscape.
Uncover the wide-ranging economic and quality of life benefits possible with the Edwards SAPIEN 3 transcatheter heart valve.7
Useful for you and your patients, including heart anatomy guide, clinical summary PDFs and more.
Access resourcesThank you for signing up to the heartvalves.com newsletter. You will now receive emails on the latest developments and industry insights on heart valve innovation and technology.
References:
1. Mack MJ, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1695-1705.
2. Tarantini G, et al. Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve. Circ Cardiovasc Interv. 2020 Jul;13(7):e008972.
3. Pibarot P, et al. Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial. J Am Coll Cardiol. 2020 Oct 20;76(16):1830-1843.
4. Leon MB, et al. N Engl J Med 2016;374:1609-1620 and supplementary material.
5. Leon MB, Smith CR, Mack M, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-607.
6. Smith CR, Leon MB, Mack MJ, et al.; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-98.
7. Galper BZ, et al. Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial. Circulation. 2023 May 23;147(21):1594-1605.
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
Edwards, Edwards Lifesciences, the stylized E logo, Edwards Benchmark, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra, PARTNER, PARTNER II, and PARTNER 3 are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property if their respective owners.
PP--EU-6940 v1.0
